Reuters logo
BRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer
December 5, 2017 / 12:25 PM / 8 days ago

BRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer

Dec 5 (Reuters) - Oncolytics Biotech Inc:

* ONCOLYTICS BIOTECH® RECEIVES FAVORABLE FINAL ADVICE LETTER FROM THE EUROPEAN MEDICINES AGENCY FOR REOLYSIN® IN METASTATIC BREAST CANCER

* ONCOLYTICS BIOTECH INC - PROPOSED PHASE 3 STUDY DESIGN IS FOUND ACCEPTABLE AND CAN FORM BASIS OF A MARKETING AUTHORIZATION APPLICATION

* ONCOLYTICS BIOTECH INC - EMA ADVICE CONSISTENT WITH FEEDBACK RECEIVED FROM FDA PAVING WAY FOR A GLOBAL PHASE 3 STUDY Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below